| Date | Title | Description |
| 21.09.2026 | C2N Diagnostics Expands Global Partnerships in United Kingdom on World Alzheimer’s Day, Joins Cambridge Cognition and The Alzheimer’s Trust to Improve Alzheimer’s Disease Diagnosis | - |
| 28.05.2026 | Cambridge Cognition and Oura launch large-scale brain health study integrating cognition with wearable sleep and physiological data | Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces a collaboration with ŌURA, make... |
| 01.09.2025 | Placing and subscription raising approximately £1.12 million, total voting tights and PDMR dealings | Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce that following the announcement of its interim res... |
| 10.04.2025 | Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial | Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessment... |
| 11.03.2024 | Cognitive Assessment And Training Market Size, Share And Growth Analysis For 2024-2033 | Cognitive Assessment And Training Global Market Report 2024 – Market Size, Trends, And Market Forecast 2024-2033
The Business Research Company’s Cognitive Assessment And Training Global Market Report 2024 – Market Size, Trends, And Market F... |
| 08.09.2022 | Real-World Measurement of Cognition and Mood in Frontline COVID-19 Healthcare Workers, Upcoming Webinar Hosted by Xtalks | The featured speakers introduce the stress and recovery study design approach and discuss a sub-analysis of this study conducted by 4YouandMe and Cambridge Cognition that focuses on real-world measurement of mood and cognition among the stu... |
| 22.03.2022 | Successful Statistical Strategies for Patient Screening and Stratification, Upcoming Webinar Hosted by Xtalks | By considering the value of data available throughout every stage of a cognitive study, the potential to detect an efficacy signal can be increased.
TORONTO (PRWEB) March 22, 2022
The outcome of clinical trials is often determined by the qu... |
| 22.12.2021 | SOFTWARE AS A MEDICAL DEVICE (SaMD) Часть 3: сертифицированные MedTech стартапы на основе искусственного интеллекта (AI) | SOFTWARE AS A MEDICAL DEVICE (SaMD) Часть 3: сертифицированные MedTech стартапы на основе искусственного интеллекта (AI) |
| 22.12.2021 | SOFTWARE AS A MEDICAL DEVICE (SaMD) Part 3: Certified AI-based MedTech Startups | SOFTWARE AS A MEDICAL DEVICE (SaMD) Part 3: Certified AI-based MedTech Startups |
| 16.12.2021 | Cambridge Cognition : Electronic Clinical Outcomes Assessment contract win worth over £500,000 | Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments ("eCOA") to support... |
| 27.10.2021 | Decentralised Trials in Psychiatry: From Feasibility to Novel Insights, Upcoming Webinar Hosted by Xtalks | Psychiatry stands to benefit from the decentralisation of trials, yet new technologies and new ways of working have yet to be widely adopted.
TORONTO (PRWEB) October 27, 2021
Many patients struggle to participate in clinical trials because ... |
| 12.10.2021 | Novel Digital Technologies and Biomarkers to Characterise Depression, Upcoming Webinar Hosted by Xtalks | In efforts to address this question, Novartis evaluated seven digital technologies spanning eye-tracking in the clinic to the daily use of a Cambridge Cognition mobile app at home.
TORONTO (PRWEB) October 12, 2021
The development of new tre... |
| 02.07.2021 | Cambridge Cognition completes spin-out of Monument Therapeutics | Cambridge Cognition completes spin-out of Monument Therapeutics
02-07-2021
Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to centra... |
| 29.06.2021 | Cambridge Cognition wins new £2.2 million contract for at-home cognitive testing in a virtual clinical trial | Cambridge Cognition wins new £2.2 million contract for at-home cognitive testing in a virtual clinical trial
29-06-2021
Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is val... |
| 11.05.2021 | Cambridge Index falls 1.3% | Cambridge Index falls 1.3%
11-05-2021
The Cambridge Index declined 359.3 points or 1.3% to close at 27670.1, as five of the top ten Index heavyweights posted weekly losses to their share prices.
Johnson Matthey, up 0.7%, announced a further... |
| 23.03.2021 | Will new behavioral health solutions withstand the test of time? | Unsurprisingly, there are plenty of talented companies eager to join in the quest for better behavioral health data. Quartet Health created a technology platform that integrates data sources to more precisely identify patients who might nee... |
| 04.07.2018 | CANTAB technology selected for world’s largest dementia study | CANTAB technology selected for world’s largest dementia study
04-07-2018
Cambridge Cognition Holdings PLC (AIM: COG), the digital neuroscience company which develops and markets software products to assess brain health, is pleased to announ... |
| 11.04.2018 | CANTAB Recruit contracts show strong growth for Cambridge Cognition | CANTAB Recruit contracts show strong growth for Cambridge Cognition
11-04-2018
Cambridge Cognition Holdings PLC, (AIM: COG) the digital neuroscience company which develops and markets software products to assess brain health, is pleased to ... |
| 29.03.2018 | Cambridge Cognition announces major contract win and funding award | Cambridge Cognition announces major contract win and funding award
29-03-2018
The digital neuroscience company Cambridge Cognition Holdings PLC, (AIM: COG) which develops and markets software products to improve brain health, is pleased to ... |
| 29.03.2018 | Cambridge Cognition announces major contract win and funding award | The digital neuroscience company Cambridge Cognition Holdings PLC, (AIM: COG) which develops and markets software products to improve brain health, is pleased to announce the award of a major new pharmaceutical clinical trial contract and a... |
| 09.10.2015 | 30 years on, CANTAB inventors herald the dawn of a new era in neuroscience | 30 years on, CANTAB inventors herald the dawn of a new era in neuroscience
09-10-2015
Three decades ago two emerging neuroscientists, Barbara Sahakian and Trevor Robbins from University of Cambridge, received a grant to fund their developme... |
| 17.06.2015 | Preparing for AIM listing? Maximise your company’s value | Preparing for AIM listing? Maximise your company’s value
17-06-2015
Marketing is often considered an afterthought for science and technology companies preparing for an IPO, but according to Simon Fryer, CEO at KISS, sorting out a company’s ... |
| 17.06.2015 | Preparing for AIM listing? Maximise your company’s value | Marketing is often considered an afterthought for science and technology companies preparing for an IPO, but according to Simon Fryer, CEO at KISS, sorting out a company’s brand proposition, marketing collateral and profile will help achiev... |
| 14.04.2015 | Cambridge Cognition product exceeds £1m sales in first nine months | Cambridge Cognition product exceeds £1m sales in first nine months
14-04-2015
Cambridge Cognition today announces that sales of its Cantab Connect CTIS-Abuse Liability have exceeded £1 million ($1.5 million) in its first nine months from la... |
| 27.06.2014 | Cambridge Cognition wins significant contracts | Cambridge Cognition wins significant contracts
27-06-2014
Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the acceleration of safe and effective medicines in ... |
| 19.04.2013 | Cambridge Cognition IPO raises £6.4million | Cambridge Cognition IPO raises £6.4million
19-04-2013
Cambridge Cognition, the leading British developer of computerised neuropsychological tests, has floated on London’s Alternative Investment Market (AIM). The listing, which took place ye... |
| - | Will new behavioral health solutions withstand the test of time? | The digitization of care prompted by the recent pandemic has only resulted in a heightened level of excitement and support for innovations in a field where advancement has been slow. As healthcare investors, we certainly welcome this – ther... |
